BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Buti M, Homs M. Nuevos agentes para el tratamiento de la hepatitis C. Enfermedades Infecciosas y Microbiología Clínica 2012;30:147-50. [DOI: 10.1016/j.eimc.2011.09.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 López-villaescusa M, Pérez-garcía L, Rodríguez-vázquez M, Martínez-martínez M. Toxicidad cutánea por telaprevir: un nuevo fármaco que es necesario conocer. Actas Dermo-Sifiliográficas 2014;105:317-9. [DOI: 10.1016/j.ad.2013.04.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
2 García-Sierra RM, Feijoo-Cid M, Font-Canals R, Varoucha-Azcarate AC, Bernal-Balada R, López-Parra M, Caballero-Sáez I, Pérez-Bernal M; Grup de Recerca Infermera en Hepatitis C (GRIHep). [Validation of the Spanish version of the HIV Related Fatigue Scale and application in people with hepatitis C]. Enferm Clin 2015;25:245-53. [PMID: 26145731 DOI: 10.1016/j.enfcli.2015.04.001] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Llanes MS, Palacios NS, Piccione M, Ruiz MG, Layana C. [Molecular aspects of the antiviral response against hepatitis C virus implicated in vaccines development]. Enferm Infecc Microbiol Clin 2015;33:273-80. [PMID: 24529681 DOI: 10.1016/j.eimc.2013.12.012] [Reference Citation Analysis]
4 Toro Montecinos M, Carrascosa Carrillo JM, Vilavella Rius M, Bielsa Marsol I, Plana Pla A, Morillas Cunill R, Planas Vilà R, Masnou Ridaura H, López Escartin D, Ferrándiz Foraster C. Drug eruptions induced by telaprevir in patients with chronic hepatitis C virus genotype 1 infection: a prospective study. Actas Dermosifiliogr 2015;106:219-25. [PMID: 25444579 DOI: 10.1016/j.ad.2014.07.004] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]